Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ren Liu

Showing results (841-850 of 874) with videos related to

Pageof 88
Sort By:
Annals of Translational Medicine|May 13, 2020
Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resectionWei-Feng Qu, Pei-Yun Zhou, Wei-Ren Liu, et al.
Cell Discovery|March 6, 2023
CD36<sup>+</sup> cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factorGui-Qi Zhu, Zheng Tang, Run Huang, et al.
BMC Medicine|June 6, 2019
Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinomaMeng-Xin Tian, Wei-Ren Liu, Han Wang, et al.
Signal Transduction and Targeted Therapy|January 21, 2025
Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8<sup>+</sup>T and tumor cellsGui-Qi Zhu, Zheng Tang, Tian-Hao Chu, et al.
Nature|June 11, 2025
Brain implantation of soft bioelectronics via embryonic developmentHao Sheng, Ren Liu, Qiang Li, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|September 8, 2020
Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti-Programmed Death 1 Immunotherapy for Recurrent Liver TumorsGuo-Ming Shi, Jiping Wang, Xiao-Wu Huang, et al.
Chemical & Biomedical Imaging|June 30, 2023
Early Detection and Staging of Lung Fibrosis Enabled by Collagen-Targeted MRI Protein Contrast AgentOluwatosin Y Ibhagui, Dongjun Li, Hongwei Han, et al.
BJS Open|September 20, 2022
Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world studyWei-Feng Qu, Zhen-Bin Ding, Xu-Dong Qu, et al.
Science Advances|May 2, 2025
Targeting HMGB2 acts as dual immunomodulator by bolstering CD8<sup>+</sup> T cell function and inhibiting tumor growth in hepatocellular carcinomaWei-Feng Qu, Gui-Qi Zhu, Rui Yang, et al.
Cancer Letters|December 10, 2025
Application of targeted deep sequencing for management of hepatocellular carcinoma in a real-world setting: prediction of MRD and adjuvant lenvatinib responseShi-Yu Zhang, De-Zhen Guo, Xin Zhang, et al.
Pageof 88

Showing results (841-850 of 874) with videos related to

Sort By:
Pageof 88
Annals of Translational Medicine|May 13, 2020
Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resectionWei-Feng Qu, Pei-Yun Zhou, Wei-Ren Liu, et al.
Cell Discovery|March 6, 2023
CD36<sup>+</sup> cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factorGui-Qi Zhu, Zheng Tang, Run Huang, et al.
BMC Medicine|June 6, 2019
Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinomaMeng-Xin Tian, Wei-Ren Liu, Han Wang, et al.
Signal Transduction and Targeted Therapy|January 21, 2025
Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8<sup>+</sup>T and tumor cellsGui-Qi Zhu, Zheng Tang, Tian-Hao Chu, et al.
Nature|June 11, 2025
Brain implantation of soft bioelectronics via embryonic developmentHao Sheng, Ren Liu, Qiang Li, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|September 8, 2020
Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti-Programmed Death 1 Immunotherapy for Recurrent Liver TumorsGuo-Ming Shi, Jiping Wang, Xiao-Wu Huang, et al.
Chemical & Biomedical Imaging|June 30, 2023
Early Detection and Staging of Lung Fibrosis Enabled by Collagen-Targeted MRI Protein Contrast AgentOluwatosin Y Ibhagui, Dongjun Li, Hongwei Han, et al.
BJS Open|September 20, 2022
Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world studyWei-Feng Qu, Zhen-Bin Ding, Xu-Dong Qu, et al.
Science Advances|May 2, 2025
Targeting HMGB2 acts as dual immunomodulator by bolstering CD8<sup>+</sup> T cell function and inhibiting tumor growth in hepatocellular carcinomaWei-Feng Qu, Gui-Qi Zhu, Rui Yang, et al.
Cancer Letters|December 10, 2025
Application of targeted deep sequencing for management of hepatocellular carcinoma in a real-world setting: prediction of MRD and adjuvant lenvatinib responseShi-Yu Zhang, De-Zhen Guo, Xin Zhang, et al.
Pageof 88